Skip to main content
. 2021 Aug 20;16:62–64. doi: 10.1016/j.jdcr.2021.08.012

Fig 1.

Fig 1

Clinical images of cutaneous involvement (A) at presentation, (B) after 3 months of tofacitinib, and (C) after 6 months of tofacitinib.